Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06069791 · ClinicalTrials.gov registry record · Phase 1

Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1

A Phase 1 study of Post-Traumatic Headache, sponsored by Yale University.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT06069791 is a Phase 1 study of Post-Traumatic Headache that is actively recruiting participants, run by Yale University. The registered enrollment target is 12 participants, below the 100-participant average among 8 other Post-Traumatic Headache trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06069791, a Phase 1 study of Post-Traumatic Headache, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The acute and subacute sensations that occur on the scalp with injection of different concentrations of bupivacaine for grater occipital nerve blockade will be compared. Each Veteran participant will be randomized to receive three different concentrations, which will be injected one week apart each.

Conditions Studied

Interventions

  • DRUG Bupivacaine Injection

Study Locations (1)

Connecticut

  • VA Connecticut Healthcare System - West Haven

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2024-01-26
Est. Completion 2026-12-31
Phase Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT06069791

The ClinicalTrials.gov registry entry for NCT06069791 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 8 other Post-Traumatic Headache trials with a reported enrollment target (88% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Post-Traumatic Headache appearing as the primary indexed condition, and to 1 intervention - of which Bupivacaine Injection is the first listed.

NCT06069791 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT06069791 about?

NCT06069791 is a clinical study titled "Greater Occipital Nerve Blockade in Veterans With Post-concussion Headache: Sub-study 1". The acute and subacute sensations that occur on the scalp with injection of different concentrations of bupivacaine for grater occipital nerve blockade will be compared. Each Veteran participant will be randomized to receive three different concentrations, which will be injected one week apart each.

What is the current status of trial NCT06069791?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-01-26. Estimated completion is 2026-12-31.

What conditions does trial NCT06069791 study?

This clinical trial studies the following conditions: Post-Traumatic Headache.

What interventions are being tested in trial NCT06069791?

The interventions under investigation include: Bupivacaine Injection (DRUG).

Who is sponsoring clinical trial NCT06069791?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06069791 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Post-Traumatic Headache

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.